par Drägerwerk AG & Co. KGaA (ETR:DRW8)
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures 2025: Record net sales and significant earnings growth – forecast for 2026
EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Forecast
Drägerwerk AG & Co. KGaA: Preliminary figures 2025: Record net sales and significant earnings growth – forecast for 2026
15-Jan-2026 / 14:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
Ad-hoc notification in accordance with Sec. 17 of the MAR
Drägerwerk AG & Co. KGaA: Preliminary figures 2025: Record net sales and significant earnings growth – forecast for 2026
Lübeck, January 15, 2026 – Based on preliminary calculations, Dräger's net sales rose by 5.3 percent in fiscal year 2025 (net of currency effects; nominal: 3.3 percent). Following a very strong year-end business, this was slightly above the last forecast, according to which Dräger had expected an increase in a range of 3.0 to 5.0 percent (net of currency effects). At around EUR 3,482 million, net sales reached the highest level in the Company's history (2024: EUR 3,370.9 million).
Both divisions contributed to the record net sales: after a decline in the prior year, the medical division recorded growth of 7.4 percent (net of currency effects; nominal: 5.1 percent) to around EUR 1,996 million (2024: EUR 1,899.7 million), while the safety division grew by 2.5 percent (net of currency effects; nominal: 1.0 percent) to around EUR 1,486 million (2024: EUR 1,471.2 million). The Group's gross margin increased to around 45.4 percent (2024: 44.9 percent), partly due to the good performance in the fourth quarter.
Earnings before interest and taxes (EBIT) rose significantly to around EUR 226 to 236 million (2024: EUR 194.0 million). The EBIT margin increased to around 6.5 to 6.8 percent (2024: 5.8 percent). This was above the last forecast, according to which Dräger had expected an EBIT margin in the range of 4.5 to 6.5 percent.
Order intake rose by 7.9 percent (net of currency effects; nominal: 5.8 percent) to around EUR 3,575 million. This significantly exceeded the prior-year figure (2024: EUR 3,380.5 million). Both divisions contributed to this growth: in the medical division, order intake rose significantly by 9.0 percent (net of currency effects; nominal: 6.5 percent) to around EUR 2,049 million (2024: EUR 1,924.1 million). In the safety division, order intake increased by 6.3 percent (net of currency effects; nominal: 4.8 percent) to around EUR 1,526 million (2024: EUR 1,456.4 million).
Dividend proposal
In line with the existing dividend policy, Dräger intends to distribute around 30 percent of the group net profit to its shareholders. The final dividend proposal will be made with the final business figures for 2025.
Forecast for 2026
Due to the good order intake, Dräger expects an increase in net sales of 1.0 to 5.0 percent (2.0 to 6.0 percent net of currency effects) and an EBIT margin of 5.0 to 7.5 percent for the current fiscal year.
The full 2025 Annual Report will be published on March 24, 2026.
Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com
Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com
Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
melanie.kamann@draeger.com
Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.
End of Inside Information
15-Jan-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News
| Language: | English |
| Company: | Drägerwerk AG & Co. KGaA |
| Moislinger Allee 53-55 | |
| 23558 Lübeck | |
| Germany | |
| Phone: | +49 (0)451 882-0 |
| Fax: | +49 (0)451 882-2080 |
| E-mail: | info@draeger.com |
| Internet: | www.draeger.com |
| ISIN: | DE0005550602, DE0005550636 (Vorzugsaktien) |
| WKN: | 555060, 555063 (Vorzugsaktien) |
| Indices: | SDAX, TecDax |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2260714 |
| End of Announcement | EQS News Service |
2260714 15-Jan-2026 CET/CEST